Clostridioides difficile infection (CDI) is a significant cause of healthcare-associated infections, ranging from mild diarrhea to life-threatening colitis. CDI typically occurs after antibiotic use, which disrupts the normal gut microbiota, allowing C. difficile to proliferate. Early and accurate identification of CDI severity is critical for effective management and to prevent complications. Management of CDI is guided by clinical severity, with treatments tailored for non-severe, severe, or fulminant presentations. Recurrent infections are common, requiring specific protocols for effective treatment. Recent updates in the management of CDI emphasize newer agents like fidaxomicin and adjunctive therapies such as bezlotoxumab, offering better outcomes in preventing recurrences [1–3] [Ref: Algorithm 42.1].